Cargando…

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients

PURPOSE: The availability of different routes of administration of rituximab, with different dosing and times of infusion in the day care unit, raises the question of which formulation would be the best in terms of direct cost, particularly with the approval of new intravenous (IV) rituximab biosimi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delgado Sánchez, Olga, Gutiérrez, Antonio, do Pazo, Fernando, Ginés, Jordi, Martorell, Clara, Boyeras, Bàrbara, Bento, Leyre, Garcia-Recio, Marta, Sampol, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874115/ https://www.ncbi.nlm.nih.gov/pubmed/31819561 http://dx.doi.org/10.2147/CEOR.S212257

Ejemplares similares

Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma
por: Garcia-Recio, Marta, et al.
Publicado: (2018)

Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report
por: Garcia-Recio, Marta, et al.
Publicado: (2016)

Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience
por: García-Recio, Marta, et al.
Publicado: (2017)

Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
por: Theodore-Oklota, Christina, et al.
Publicado: (2016)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
por: Gutierrez, Antonio, et al.
Publicado: (2014)

Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience
por: Gutierrez, Antonio, et al.
Publicado: (2023)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Thermolabile drug storage in an ambulatory setting
por: do Pazo-Oubiña, Fernando, et al.
Publicado: (2021)

Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation
por: Bento, Leyre, et al.
Publicado: (2022)

Prognostic Role of the Red Blood Cell Distribution Width (RDW) in Hodgkin Lymphoma
por: Herraez, Ines, et al.
Publicado: (2020)

Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
por: Harvey, Michael J., et al.
Publicado: (2022)

Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
por: Mao, Cheng-Ping, et al.
Publicado: (2013)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
por: Ponzetti, Clemente, et al.
Publicado: (2016)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)

Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma
por: Herraez, Ines, et al.
Publicado: (2021)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab
por: Menzer, Christian, et al.
Publicado: (2022)

Analysis of Personality Traits in Patients with Hodgkin Lymphoma
por: Roso-Bas, Fatima, et al.
Publicado: (2021)

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study
por: García‐Muñoz, Ricardo, et al.
Publicado: (2019)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
por: Galecio, Juan Sebastián, et al.
Publicado: (2020)

Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration
por: Fadel, Charbel, et al.
Publicado: (2022)

Disposition Kinetic of Moxifloxacin following Intravenous, Intramuscular, and Subcutaneous Administration in Goats
por: Patel, Harshad B., et al.
Publicado: (2011)

Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits
por: Drobnjak, Tijana, et al.
Publicado: (2018)

Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration
por: Walters, Rodney R., et al.
Publicado: (2021)

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
por: Lugtenburg, Pieternella, et al.
Publicado: (2017)

The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection
por: Jin, Jing-fen, et al.
Publicado: (2015)

Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
por: Ashraf, Muhammad W., et al.
Publicado: (2020)

Serum concentration and safety of intravenous drip versus subcutaneous administration of carboplatin in dogs
por: IWANO, Masataka, et al.
Publicado: (2021)

Pharmacokinetics of glucagon after intravenous, intraperitoneal and subcutaneous administration in a pig model
por: Teigen, Ingrid Anna, et al.
Publicado: (2022)

Pharmacokinetics of esomeprazole in goats (Capra aegagrus hircus) after intravenous and subcutaneous administration
por: Fladung, Rachel, et al.
Publicado: (2022)

A Comparison of Subcutaneous with Intravenous and Intrathecal Administration of Tetanus Antitoxin in Experimental Tetanus
Publicado: (1918)

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
por: Dürig, Jan, et al.
Publicado: (2022)

Subcutaneous Administration of Tramadol after Elective Surgery Is as Effective as Intravenous Administration in Relieving Acute Pain and Inflammation in Dogs
por: Buhari, Salisu, et al.
Publicado: (2012)

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers
por: Soefje, Scott A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r4l8kgtph81ge50a3aa132l6gv